Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
---|---|---|---|---|---|---|---|---|---|---|---|---|
HCC70 | Alpelisib | 2 | 72 | 3.2 | 1974.0 | 2514.5 | 722.8 | 0.505 | 0.748 | 0.785 | 1.799 | HCC70 BYL719 0 2 72 |
HCC70 | CAL-101 | 2 | 72 | 0.001 | 2489.8 | 2411.0 | 722.8 | -3.0 | 1.040 | 1.030 | 1.738 | HCC70 CAL101 0 2 72 |
HCC70 | CAL-101 | 2 | 72 | 0.0032 | 2413.0 | 2411.0 | 722.8 | -2.49 | 1.000 | 1.000 | 1.738 | HCC70 CAL101 0 2 72 |
HCC70 | CAL-101 | 2 | 72 | 0.01 | 2513.5 | 2411.0 | 722.8 | -2.0 | 1.050 | 1.040 | 1.738 | HCC70 CAL101 0 2 72 |
HCC70 | CAL-101 | 2 | 72 | 0.032 | 2506.5 | 2411.0 | 722.8 | -1.49 | 1.050 | 1.040 | 1.738 | HCC70 CAL101 0 2 72 |
HCC70 | CAL-101 | 2 | 72 | 0.1 | 2401.0 | 2411.0 | 722.8 | -1.0 | 0.995 | 0.996 | 1.738 | HCC70 CAL101 0 2 72 |
HCC70 | CAL-101 | 2 | 72 | 0.32 | 2385.8 | 2411.0 | 722.8 | -0.495 | 0.988 | 0.990 | 1.738 | HCC70 CAL101 0 2 72 |
HCC70 | CAL-101 | 2 | 72 | 1.0 | 1993.5 | 2411.0 | 722.8 | 0.0 | 0.793 | 0.827 | 1.738 | HCC70 CAL101 0 2 72 |
HCC70 | CAL-101 | 2 | 72 | 3.2 | 1670.8 | 2411.0 | 722.8 | 0.505 | 0.620 | 0.693 | 1.738 | HCC70 CAL101 0 2 72 |
HCC70 | Everolimus | 2 | 72 | 0.001 | 1933.0 | 2397.8 | 722.8 | -3.0 | 0.766 | 0.806 | 1.730 | HCC70 Everolimus 0 2 72 |
HCC70 | Everolimus | 2 | 72 | 0.0032 | 1925.8 | 2397.8 | 722.8 | -2.49 | 0.762 | 0.803 | 1.730 | HCC70 Everolimus 0 2 72 |
HCC70 | Everolimus | 2 | 72 | 0.01 | 2085.3 | 2397.8 | 722.8 | -2.0 | 0.845 | 0.870 | 1.730 | HCC70 Everolimus 0 2 72 |
HCC70 | Everolimus | 2 | 72 | 0.032 | 1952.8 | 2397.8 | 722.8 | -1.49 | 0.776 | 0.814 | 1.730 | HCC70 Everolimus 0 2 72 |
HCC70 | Everolimus | 2 | 72 | 0.1 | 1971.8 | 2397.8 | 722.8 | -1.0 | 0.786 | 0.822 | 1.730 | HCC70 Everolimus 0 2 72 |
HCC70 | Everolimus | 2 | 72 | 0.32 | 1894.3 | 2397.8 | 722.8 | -0.495 | 0.745 | 0.790 | 1.730 | HCC70 Everolimus 0 2 72 |
HCC70 | Everolimus | 2 | 72 | 1.0 | 1950.3 | 2397.8 | 722.8 | 0.0 | 0.775 | 0.813 | 1.730 | HCC70 Everolimus 0 2 72 |
HCC70 | Everolimus | 2 | 72 | 3.2 | 1762.5 | 2397.8 | 722.8 | 0.505 | 0.674 | 0.735 | 1.730 | HCC70 Everolimus 0 2 72 |
HCC70 | Pictilisib | 2 | 72 | 0.001 | 2198.5 | 2487.3 | 722.8 | -3.0 | 0.866 | 0.884 | 1.783 | HCC70 GDC0941 0 2 72 |
HCC70 | Pictilisib | 2 | 72 | 0.0032 | 2541.0 | 2487.3 | 722.8 | -2.49 | 1.020 | 1.020 | 1.783 | HCC70 GDC0941 0 2 72 |
HCC70 | Pictilisib | 2 | 72 | 0.01 | 2561.3 | 2487.3 | 722.8 | -2.0 | 1.030 | 1.030 | 1.783 | HCC70 GDC0941 0 2 72 |
HCC70 | Pictilisib | 2 | 72 | 0.032 | 2442.5 | 2487.3 | 722.8 | -1.49 | 0.980 | 0.982 | 1.783 | HCC70 GDC0941 0 2 72 |
HCC70 | Pictilisib | 2 | 72 | 0.1 | 2392.8 | 2487.3 | 722.8 | -1.0 | 0.957 | 0.962 | 1.783 | HCC70 GDC0941 0 2 72 |
HCC70 | Pictilisib | 2 | 72 | 0.32 | 1967.0 | 2487.3 | 722.8 | -0.495 | 0.753 | 0.791 | 1.783 | HCC70 GDC0941 0 2 72 |
HCC70 | Pictilisib | 2 | 72 | 1.0 | 1383.5 | 2487.3 | 722.8 | 0.0 | 0.439 | 0.556 | 1.783 | HCC70 GDC0941 0 2 72 |
HCC70 | Pictilisib | 2 | 72 | 3.2 | 890.3 | 2487.3 | 722.8 | 0.505 | 0.124 | 0.358 | 1.783 | HCC70 GDC0941 0 2 72 |